Skip to main content
Home
Courses
Home
Courses
Logout
My Profile
Logout
Back
First-in-class CDK4/6 inhibitor Palbociclib in treating broad range of women with HR+, HER2- metastatic Breast Cancer
First-in-class CDK4/6 inhibitor Palbociclib in treating broad range of women with HR+, HER2- metastatic Breast Cancer
last update on: 08/26/2024
Brands
Category
Modules
Ibrance
Oncology
1
Create an account and subscribe